HuGE Literature Finder
Records
1
-
30
| Assessment of the Link of Journal of advanced research 2021 Nov 33 141-151. Parvin Most Nazma, Aziz Md Abdul, Rabbi Sikder Nahidul Islam, Al-Mamun Mir Md Abdullah, Hanif Mohammed, Islam Md Saiful, Islam Mohammad Safiq |
| Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. International immunopharmacology 2021 Jul 98 107827. Li Ling, Zhu Min, Li De-Yi, Guo Hong-Li, Hu Ya-Hui, Xu Ze-Yue, Jing Xia, Chen Feng, Zhao Fei, Li Yun-Man, Xu Jing, Jiao Zhe |
| Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome. European journal of clinical pharmacology 2021 Jan . Liu Hongxia, Xu Qinxia, Huang Wenyan, Zhao Qi, Jiang Zhihu, Kuang Xinyu, Li Zhiling, Sun Huajun, Qiu Xiaoy |
| Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. European journal of clinical pharmacology 2020 Aug . Wang Junyan, Huang Lingfei, Gao Peng, Hu Yan, Ni Yinghua, Zhu Zhengyi, Zhang Liwen, Yang Jufei, Zhang Huifen, Fang L |
| Kidney podocyte-associated gene polymorphisms affect tacrolimus concentration in pediatric patients with refractory nephrotic syndrome. The pharmacogenomics journal 2020 Jan . Mo Xiaolan, Li Jiali, Liu Yunfeng, Liao Xin, Tan Mei, Chen Yilu, He Fan, He Yanling, Li Yingjie, Huang M |
| Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2019 Dec 143 105199. Huang Lingfei, Liu Yixi, Jiao Zheng, Wang Junyan, Fang Luo, Mao Jianh |
| Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. Molecular biology reports 2019 May . Mirzaev K B, Samsonova K I, Potapov P P, Andreev D A, Grishina E A, Ryzhikova K A, Sychev D |
| Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Scientific reports 2019 Apr 9 (1): 5404. Ozeki Tomoko, Nagahama Mitsuji, Fujita Kazuma, Suzuki Akifumi, Sugino Kiminori, Ito Koichi, Miura Masato |
| Evaluation of Genetic Polymorphisms for Determining Steroid Response in Nephrotic Children. Annals of clinical and laboratory science 2018 Jul 48 (4): 478-483. Kara Aslihan, Gurgoze Metin Kaya, Kara Murat, Aydin Musta |
| Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome. BMC pharmacology & toxicology 2018 Apr 19 (1): 14. Li Min, Xu Min, Liu Wei, Gao X |
| Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations. PloS one 2018 13 (4): e0194842. Jmel Haifa, Romdhane Lilia, Ben Halima Yosra, Hechmi Meriem, Naouali Chokri, Dallali Hamza, Hamdi Yosr, Shan Jingxuan, Abid Abdelmajid, Jamoussi Henda, Trabelsi Sameh, Chouchane Lotfi, Luiselli Donata, Abdelhak Sonia, Kefi R |
| MDR-1 and CYP3A5 Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome: Impact on Susceptibility and Response to Steroids (Preliminary Results). Clinical laboratory 2017 Jul 63 (7): 1233-1242. Moussa Amira, Mabrouk Sameh, Hamdouni Haithem, Ajmi Maroua, Tfifha Miniar, Omezzine Asma, Abroug Saoussen, Bouslama A |
| A Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic Information. PloS one 2017 12 (1): e0169214. Silva-Alves Mariana S, Secolin Rodrigo, Carvalho Benilton S, Yasuda Clarissa L, Bilevicius Elizabeth, Alvim Marina K M, Santos Renato O, Maurer-Morelli Claudia V, Cendes Fernando, Lopes-Cendes Isc |
| Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome. Physiological research 2016 Dec 65 (Supplementum 4): S463-S472. Hronová K, Pokorná P, Posch L, Slana? |
| Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib. Anti-cancer drugs 2016 Aug . Numakura Kazuyuki, Tsuchiya Norihiko, Kagaya Hideaki, Takahashi Makoto, Tsuruta Hiroshi, Inoue Takamitsu, Narita Shintaro, Huang Mingguo, Satoh Shigeru, Niioka Takenori, Miura Masatomo, Habuchi Tomono |
| Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen? Drug metabolism and personalized therapy 2016 Jul . Falvella Felicia Stefania, Marelli Susan, Cheli Stefania, Montanelli Stefano, Viecca Federico, Salvi Lucia, Ferrara Alfio, Clementi Emilio, Trifirò Giuliana, Pini Alessand |
| Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome. Therapeutic drug monitoring 2016 Apr . Teeninga Nynke, Guan Zheng, Stevens Jasper, Kist-van Holthe Joana E, Ackermans Mariëtte T, van der Heijden Albert J, van Schaik Ron H N, van Gelder Teun, Nauta Jero |
| Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. International journal of laboratory hematology 2015 Aug . Arya V, Mahajan P, Saraf A, Mohanty A, Sawhney J P S, Bhargava |
| Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention. International journal of clinical and experimental medicine 2015 8 (6): 9266-74. Chen Yu, Huang Xiaohong, Tang Yong, Xie Yuquan, Zhang Yach |
| Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. European journal of clinical pharmacology 2013 Nov 69 (11): 1909-16. Ciccacci Cinzia, Di Fusco Davide, Marazzi Maria C, Zimba Ines, Erba Fulvio, Novelli Giuseppe, Palombi Leonardo, Borgiani Paola, Liotta Giusep |
| Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer chemotherapy and pharmacology 2013 Oct 72 (4): 825-35. Kim Hye Ryun, Park Hyung Soon, Kwon Woo Sun, Lee Ji Hyun, Tanigawara Yusuke, Lim Sun Min, Kim Hyo Song, Shin Sang Jun, Ahn Jung Bae, Rha Sun You |
| Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatric nephrology (Berlin, Germany) 2012 Sep 27 (9): 1511-7. Chiou Yee-Hsuan, Wang Lin-Yu, Wang Tzu-Hui, Huang Shiao-pi |
| The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. American journal of obstetrics and gynecology 2012 May 206 (5): 447.e17-24. Haas David M, Lehmann Amalia S, Skaar Todd, Philips Santosh, McCormick Catherine L, Beagle Kyle, Hebbring Scott J, Dantzer Jessica, Li Lang, Jung Jees |
| Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone marrow transplantation 2011 Jan 46 (1): 90-7. Yanagisawa R, Katsuyama Y, Shigemura T, Saito S, Tanaka M, Nakazawa Y, Sakashita K, Shiohara M, Koike |
| Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. Toxicology and applied pharmacology 2010 Nov 248 (3): 285-92. De Luca Chiara, Scordo Maria G, Cesareo Eleonora, Pastore Saveria, Mariani Serena, Maiani Gianluca, Stancato Andrea, Loreti Beatrice, Valacchi Giuseppe, Lubrano Carla, Raskovic Desanka, De Padova Luigia, Genovesi Giuseppe, Korkina Liudmila |
| Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. European journal of clinical pharmacology 2009 Apr 65 (4): 355-63. Veiga M I, Asimus S, Ferreira P E, Martins J P, Cavaco I, Ribeiro V, Hai T N, Petzold M G, Björkman A, Ashton M, Gil J |
| Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart and vessels 2009 Mar 24 (2): 73-8. Brackbill Marcia L, Kidd Robert S, Abdoo April D, Warner James G, Harralson Arthur |
| CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008 Sep 9 (9): 1251-9. Geisler Tobias, Schaeffeler Elke, Dippon Juergen, Winter Stefan, Buse Verena, Bischofs Christian, Zuern Christine, Moerike Klaus, Gawaz Meinrad, Schwab Matthi |
| Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002 Nov 12 (8): 605-11. Blanco Javier G, Edick Mathew J, Hancock Michael L, Winick Naomi J, Dervieux Thierry, Amylon Michael D, Bash Robert O, Behm Frederick G, Camitta Bruce M, Pui Ching-Hon, Raimondi Susana C, Relling Mary |
| Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncology reports 0 9 (2): 327-9. Liu Ta-Chih, Lin Sheng-Fung, Chen Tyen-Po, Chang Jan-Gow |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: